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We thank Garrahy and colleagues for their interest and constructive comment on our paper. They report a challenging case of Graves’ disease (GD) in early pregnancy, 15 months after alemtuzumab treatment. We wish to highlight our experience of another such case, with an aggressive maternal and fetal course.
A 27 year old female primigravida at 28+3 weeks gestation, with no prior history of thyroid disease, developed symptomatic GD [TSH <0.03 mU/L, free T4 43.7 pmol/L, RR 10.0-19.8 pmol/L, FT3 26 pmol/L RR 3.5-6.5 pmol/L), TSH receptor antibodies (TRAB) >40 iu/L (0.0-1.0 IU/L] 22 months post alemtuzumab therapy for multiple sclerosis (MS). To maximise likelihood of normalising FT3 levels we treated her with propylthiouracil (PTU) and she required high dosage (200-300mg/day) to achieve and maintain normal thyroid status and remains on antithyroid drug treatment at 18 months postpartum.  Although ultrasound scans in third trimester showed normal fetal growth and heart rate with no goitre, neonatal hyperthyroidism [day 3: TSH <0.03 mU/L, FT4 35.1 pmol/L (RR 10.0-19.8 pmol/L), FT3 23.1 (RR 3.5-6.5 pmol/L) and TRAB >40 IU/L (RR 0.0-1.0 iu/L] was evident soon after delivery at 35+6 weeks, necessitating carbimazole (CBZ) treatment (750mcg/kg/day) to normalise thyroid status [day 24: TSH <0.03 mU/L (RR 0.27-4.5), FT4 10.2 pmol/L (11-23 pmol/L)]. Withdrawal of CBZ (age 1 month), resulted in persistent hyperthyroidism [TSH <0.01, FT4 >100 pmol/L (RR 11-23), FT3 46.7pmol/L (RR 3.1-6.8)], attributable to positive neonatal TRAB levels (4.6 U/L, RR 1-1.8), requiring recommencement of CBZ and continuation of treatment till age 3 months. Neonatal weight gain (25-50th percentile) and developmental milestones were appropriate.                                              
This case, together with the patient described by Garraghy et al (1), highlight the aggressive behaviour of alemtuzumab-induced GD in pregnancy, with high TRAB levels likely mediating persistent GD following onset in first trimester or third trimester, and associated with propensity to significant, neonatal thyrotoxicosis of prolonged duration, requiring antithyroid drug treatment. Moreover, given onset of GD 15 or 22 months after alemtuzumab in these patients, we agree that monitoring of thyroid status is warranted prior to and during planned pregnancy and note that this is recommended in forthcoming guidelines on management of thyroid dysfunction following immune reconstitution (alemtuzumab) therapy (2).
Whilst we could ascertain occurrence of pregnancies we are not certain of reliably documenting thyroid outcomes retrospectively in our alemtuzumab-treated MS patient cohort and suggest that prospective evaluation of this is warranted. Furthermore, given fluctuating thyroid dysfunction in alemtuzumab-induced GD outwith of pregnancy (3), we suggest that measurement of both TRAB levels and bioactivity (stimulating, blocking) in alemtuzumab-treated patients during pregnancy and correlating this with maternal and fetal outcome, could be of interest.
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